Ming-Chao Tsai
Overview
Explore the profile of Ming-Chao Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Lee M, Lee Y, Huang S, Chang C, Ko C, Lee W, et al.
Genes (Basel)
. 2022 Apr;
13(4).
PMID: 35456435
Clear cell renal cell carcinoma (ccRCC) is the most common RCC subtype with a high mortality. It has been reported that delta-like 1 homologue (DLK1) participates in the tumor microenvironmental...
22.
Chuang C, Chen P, Bai C, Wu Y, Tsai M, Li C
J Pers Med
. 2022 Mar;
12(3).
PMID: 35330471
Spinal cord injury (SCI) is a devastating disorder. Alcohol abuse has been recognized as hindering SCI patients from rehabilitation, thus leading to longer length of days and poorer prognosis. This...
23.
Tsai M, Wang C, Lee W, Lin C, Chang K, Chen C, et al.
Liver Cancer
. 2022 Feb;
11(1):22-37.
PMID: 35222505
Background: It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have different effects on hepatocellular carcinoma (HCC) recurrence and death in patients receiving curative hepatectomy for hepatitis B...
24.
Chen Y, Huang K, Wang P, Chuang C, Yong C, Liu Y, et al.
Medicina (Kaunas)
. 2022 Feb;
58(2).
PMID: 35208582
: The impact of direct-acting antiviral (DAA)-based regimens on the recurrence of hepatocellular carcinoma (HCC) after successful curative hepatectomy is controversial. Aims: This study aimed to assess the association between...
25.
Lin Y, Wang P, Chuang C, Yong C, Liu Y, Huang P, et al.
Front Oncol
. 2022 Feb;
12:816472.
PMID: 35186751
Background: Non-B, non-C hepatocellular carcinoma (NBNC-HCC) may be related to metabolic syndrome, and the incidence of this tumor type is increasing annually. The definition of metabolic-associated fatty liver disease (MAFLD)...
26.
Huang Y, Lian W, Wang F, Wang P, Lin H, Tsai M, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163556
A high-fat diet is responsible for hepatic fat accumulation that sustains chronic liver damage and increases the risks of steatosis and hepatocellular carcinoma (HCC). MicroRNA-29a (miR-29a), a key regulator of...
27.
Tsai M, Hung C, Lu S, Wang J, Chen C, Kee K, et al.
Biomed J
. 2022 Feb;
44(6 Suppl 1):S126-S131.
PMID: 35123932
Background: Resistance-associated variants (RAVs) to direct-antiviral agents (DAAs) may hamper treatment. There was a lack of data on the natural prevalence of RAVs in Taiwanese HCV-infected patients. We investigated the...
28.
Wang J, Chen Y, Kee K, Wang C, Tsai M, Kuo Y, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053508
Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus...
29.
Chen Y, Yang S, Wang P, Wang C, Yong C, Chen D, et al.
J Pers Med
. 2021 Dec;
11(12).
PMID: 34945733
Background: Cholecystectomy has been reported to be associated with increased risk of developing hepatocellular carcinoma (HCC). However, there is little information about the impact of cholecystectomy on the outcome of...
30.
Tsai Y, Sou F, Liu Y, Wu Y, Yong C, Chen D, et al.
BMC Gastroenterol
. 2021 Oct;
21(1):386.
PMID: 34666694
Background: The albumin-bilirubin (ALBI) grade has been validated as a significant prognostic predictor for hepatocellular carcinoma (HCC). However, there is little information about the ALBI grade in patients with non-B...